Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype.

Trial Profile

Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2012

At a glance

  • Drugs Irinotecan (Primary) ; Midazolam (Primary) ; Raltegravir (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Apr 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 18 Dec 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top